
News|Videos|November 16, 2023
Advancements in Relapsed/Refractory DLBCL: An Evolving Landscape
Author(s)Matthew A. Lunning, DO, FACP
A glimpse into the ever-changing treatment landscape of DLBCL, exploring frontline therapy options and the potential for tailoring treatments based on novel agents and randomized trials.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5


















